The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride
Abstract
The modulating effects of serotonin on dopamine neurotransmission are not well understood, particularly in acute psychotic states. Positron emission tomography was used to examine the effect of psilocybin on the in vivo binding of [11C]raclopride to D2-dopamine receptors in the striatum in healthy volunteers after placebo and a psychotomimetic dose of psilocybin (n = 7). Psilocybin is a potent indoleamine hallucinogen and a mixed 5-HT2A and 5-HT1A receptor agonist. Psilocybin administration (0.25 mg/kg p.o.) produced changes in mood, disturbances in thinking, illusions, elementary and complex visual hallucinations and impaired ego-functioning. Psilocybin significantly decreased [11C]raclopride receptor binding potential (BP) bilaterally in the caudate nucleus (19%) and putamen (20%) consistent with an increase in endogenous dopamine. Changes in [11C]raclopride BP in the ventral striatum correlated with depersonalization associated with euphoria. Together with previous reports of 5-HT receptor involvement in striatal dopamine release, it is concluded that stimulation of both 5-HT2A and 5-HT1A receptors may be important for the modulation of striatal dopamine release in acute psychoses. The present results indirectly support the hypothesis of a serotonin-dopamine dysbalance in schizophrenia and suggest that psilocybin is a valuable tool in the analysis of serotonin-dopamine interactions in acute psychotic states.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparison of the two scans revealed a global 20% decline in [11C]-raclopride (41) binding in the striatum, which is similar to the displacements evoked by amphetamine or other strong releasers of dopamine.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [96]
In the citing paper
“Furthermore, the decline in the ventral striatum correlated with individual ratings for euphoria and depersonalization.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [96]
In the citing paper
“The other explanation of psychedelics' ability to facilitate altered states of consciousness characterized by heightened introspection and diminished ego boundaries is their influence on 5-HT1A [64] and 5-HT2B [65], and interacting with the dopaminergic [66] and glutamatergic systems [67].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [66]
Citations
Cites
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,025
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Self-citationPatterns of Cerebral Blood Flow in Schizophrenia
Liddle, P. F., Friston, K. J., Frith, C., Hirsch, S. R., Jones, T., & Frackowiak, R. S. J. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.2.179 · Cited by 899
Hypofrontality in Neuroleptic-Naive Patients and in Patients With Chronic Schizophrenia
Andreasen, N. C. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820120031006 · Cited by 883
Serotonin-dopamine interaction and its relevance to schizophrenia
Kapur, S., & Remington, G. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 826
The Early Symptoms of Schizophrenia
Chapman, J. (1966) · British Journal of Psychiatry · doi:10.1192/bjp.112.484.225 · Cited by 675
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Self-citationThe Mechanism of Action of Novel Antipsychotic Drugs
Meltzer, H. Y. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.263 · Cited by 412
Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics
Joyce, J. N., Shane, A. L., Lexow, N., Winokur, A., Casanova, M. F., & Kleinman, J. E. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.32 · Cited by 340
Cited by
Sorted by citations
Items 301–303 of 303
Potential Role of Psychedelics in the Treatment of Depressive Disorder
Wang, S., & Bahk, W.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_12
Thomas, J. E., & Saxena, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00043-9
Nutritional strategies to reduce fatigue-related occupational accidents among construction workers
Kolahdouzipour, F., Al-Zharani, M., Nasr, F. A., Alneghery, L. M., Alzahrani, N. S., Khalili, L., Barasarathi, J., & Sayyed, R. Z. (2026) · International Journal of Occupational Safety and Ergonomics · doi:10.1080/10803548.2026.2716446
Metadata
- Authors
- Vollenweider, F.
- Affiliations
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, F
- Venue
- Neuropsychopharmacology
- Published
- 1999-05
- Volume
- 20
- Issue
- 5
- Pages
- 424-433
- ISSN
- 0893-133X (ISSN-L)
- OpenAlex
- W1986425243
- Cited by
- 305
- References
- 73
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 28 · 2023: 28 · 2022: 20 · 2021: 18 · 2020: 19 · 2019: 6 · 2018: 13 · 2017: 7 · 2016: 14 · 2015: 7 · 2014: 6 · 2013: 9 · 2012: 11
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- psilocybin, psychosis, serotonin, dopamine release, dopamine D2 receptor, [11C]raclopride, striatum, caudate nucleus, putamen, 5-HT2A receptor, 5-HT1A receptor, serotonin-dopamine interaction, hallucinations, depersonalization, schizophrenia
- MeSH terms
- Adult, Basal Ganglia, Dopamine, Hallucinogens, Humans, Male, Psilocybin, Psychometrics, Psychoses, Substance-Induced, Salicylamides, Serotonin, Tomography, Emission-Computed, Antipsychotic Agents, Dopamine Antagonists, Raclopride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
